Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas

被引：22

作者：

Porrata, L. F. ^{[1
]}

Ristow, K.

Witzig, T. E.

Tuinistra, N.

Habermann, T. M.

Inwards, D. J.

Ansell, S. M.

Micallef, I. N.

Johnston, P. B.

Markovic, S. N.

机构：

[1] Mayo Clin, Coll Med, Dept Med, Div Hematol, Rochester, MN 55905 USA

[2] Mayo Clin, Coll Med, Dept Nucl Med, Rochester, MN USA

来源：

LEUKEMIA | 2007年 / 21卷 / 12期

关键词：

D O I：

10.1038/sj.leu.2404819

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2554 / 2556

页数：4

共 5 条

[1] Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas [J].

Behl, Deepti ;

Ristow, Kay ;

Markovic, Svetomir N. ;

Witzig, Thomas E. ;

Habermann, Thomas M. ;

Colgan, Joseph P. ;

Inwards, David J. ;

White, William L. ;

Ansell, Stephen M. ;

Micallef, Ivana N. ;

Johnston, Patrick B. ;

Porrata, Luis F. .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 (05) :409-415

[2] EVALUATION OF THE COULTER-COUNTER MODEL S-PLUS-IV [J].

COX, CJ ;

HABERMANN, TM ;

PAYNE, BA ;

KLEE, GG ;

PIERRE, RV .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1985, 84 (03) :297-306

[3]

PORRATA LF, 2004, CLIN EXP MED, V98, P579

[4] Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma [J].

Witzig, TE ;

Gordon, LI ;

Cabanillas, F ;

Czuczman, MS ;

Emmanouilides, C ;

Joyce, R ;

Pohlman, BL ;

Bartlett, NL ;

Wiseman, GA ;

Padre, N ;

Grillo-López, AJ ;

Multani, P ;

White, CA .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) :2453-2463

[5] Radioimmunotherapy for B-cell non-Hodgkin lymphoma [J].

Witzig, Thomas E. .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2006, 19 (04) :655-668

← 1 →